Jolene Wong
Clinical Assistant Professor & Consultant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Year:
2026
Year:
2026
Year:
2026
Palliative surgery is commonly performed in cancer centers worldwide. Yet, there is little agreement on the definition of palliative surgery or its relevant outcomes. This systematic review sought to characterize the definitions of palliative surgery and outcomes for patients with cancer undergoing thoraco‐abdominal procedures. Following PRISMA guidelines, we conducted a search using PubMed, EMBASE and CINAHL databases to identify English‐language publications between August 1, 2005, and December 31, 2023 reporting palliative thoraco‐abdominal procedures for patients with cancer. Definitions of palliative surgery were coded and analyzed using an inductive approach. Outcomes were classified according to an outcome measures hierarchy. Among 92 articles met inclusion criteria and four themes emerged in how palliative surgery was defined throughout the literature: prognosis (incurable cancer diagnosis), purpose (intent to treat symptoms or improve quality of life), procedure type (specific operative interventions), or persistent disease following surgery (incomplete cytoreduction). Survival (90%) and perioperative complications/morbidity (72%) were the most commonly reported outcomes, whereas symptom relief, quality of life, and sustainability of success were infrequently reported. Definitions of palliative surgery vary across studies of patients with cancer undergoing thoracic or abdominal procedures and measured outcomes often do not align with the intent of surgery.
Year:
2025
Supplementary Methods 1. Supplementary Methods, DNA extraction and whole exome sequencing, Mutation calling and mutational signatures, Whole transcriptome sequencing, Spatial profiling, Methods of A5 Discovery and Validation, Other statistical methods and reproducibility.
Year:
2025
Purpose: Peritoneal metastases (PM) in colorectal cancer portend a poor prognosis. We sought to elucidate molecular features differentiating primary tumors (PT) from PMs and actionable targets facilitating transcoelomic dissemination and progression. Experimental Design: We performed multiomic profiling of 227 samples from 136 patients, including 56 PTs and 120 synchronous PMs comprising 34 matched PT–PM pairs. Whole-exome and bulk RNA sequencing analyses were conducted to identify underlying genomic aberrations and transcriptomic differences between primary and peritoneal lesions. We spatially characterized the microenvironment of tumor–stroma compartments and studied the roles of stromal phenotypes in promulgating tumorigenesis. Results: Whole-exome sequencing found that genomic alterations and clonality patterns between PTs and PMs remain broadly similar. Transcriptomic profiles, however, suggest a transition as tumors reach the peritoneum toward a more mesenchymal tumor profile and fibrotic tumor microenvironment. Applying spatial profiling, we identify a fibro-collagenous and immune-infiltrated stromal phenotype [stromal cluster (SC) 2] characterized by increased cancer-associated fibroblasts, memory B cells, M2 macrophages, and T-cell exhaustion. These findings were orthogonally validated by multiplex IHC. Patients with SC2 stroma had poorer survival and were characterized by high SERPINE-1 ( PAI-1 ) expression. PMs in patients with SC2 stroma were associated with enriched oncogenic pathways such as TGF-β. PAI-1 inhibition of colorectal cancer PM cell lines with a novel biologic demonstrated reduced IL2–STAT5 and TGF-β pathways and cell death. Conclusions: Our findings unveil distinctive and actionable molecular signatures, offering deeper insights into the intricate cross-talk between tumor cells and stromal microenvironments enabling PM in colorectal cancer.
Year:
2025
Collaborators (10)
Samuel Klempner
Associate Professor
Massachusetts General Hospital
Joseph J Zhao
National University of Singapore
Raghav Sundar
Associate Professor
Yale University
Haoran Ma
National University of Singapore
Filippo Pietrantonio
Researcher (non-academic)
Fondazione IRCCS Istituto Nazionale dei Tumori
Lit-Hsin Loo
Senior Principal Investigator
ImmunoQs Pte Ltd
Federica Morano
Fondazione IRCCS Istituto Nazionale dei Tumori
Supriya Srivastava
Senior Research Fellow
National University Singapore Yong Loo Lin School of Medicine
Maarten F. Bijlsma
Staff scientist
Academic Medical Center
Louis Vermeulen
Group leader / PI
-
Make your next move.
Prepare your application
Review drafts before you send them.